Targeting FOXA1 and FOXA2 Disrupts the Lineage-Specific Oncogenic Output in Prostate Cancer [RNA-seq]
RNA-seq (gene expression) · human · 30 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 30 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE279872_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1174995 and SRA study SRP539520. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 10 replicated groups read from 30 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8582399 PC3, DKD, rep1 PC3, DKD,
- GSM8582400 PC3, DKD, rep2 PC3, DKD,
- GSM8582401 PC3, DKD, rep3 PC3, DKD,
- GSM8582402 PC3, DMSO, rep1 PC3, DMSO,
- GSM8582403 PC3, DMSO, rep2 PC3, DMSO,
- GSM8582404 PC3, DMSO, rep3 PC3, DMSO,
- GSM8582405 PC3, T, rep1 PC3, T,
- GSM8582406 PC3, T, rep2 PC3, T,
- GSM8582407 PC3, T, rep3 PC3, T,
- GSM8582408 PC3, PLKO, rep1 PC3, PLKO,
- GSM8582409 PC3, PLKO, rep2 PC3, PLKO,
- GSM8582410 PC3, PLKO, rep3 PC3, PLKO,
- GSM8588808 LNCaP, CTR, rep1 LNCaP, CTR,
- GSM8588809 LNCaP, CTR, rep2 LNCaP, CTR,
- GSM8588810 LNCaP, CTR, rep3 LNCaP, CTR,
- GSM8588811 LNCaP, FOXA2, rep1 LNCaP, FOXA2,
- GSM8588812 LNCaP, FOXA2, rep2 LNCaP, FOXA2,
- GSM8588813 LNCaP, FOXA2, rep3 LNCaP, FOXA2,
- GSM8588814 LNCaP, CTR-E, rep1 LNCaP, CTR-E,
- GSM8588815 LNCaP, CTR-E, rep2 LNCaP, CTR-E,
- GSM8588816 LNCaP, CTR-E, rep3 LNCaP, CTR-E,
- GSM8588817 LNCaP, FOXA2-E, rep1 LNCaP, FOXA2-E,
- GSM8588818 LNCaP, FOXA2-E, rep2 LNCaP, FOXA2-E,
- GSM8588819 LNCaP, FOXA2-E, rep3 LNCaP, FOXA2-E,
- GSM8588820 LNCaP, CTR-RES, rep1 LNCaP, CTR-RES,
- GSM8588821 LNCaP, CTR-RES, rep2 LNCaP, CTR-RES,
- GSM8588822 LNCaP, CTR-RES, rep3 LNCaP, CTR-RES,
- GSM8588823 LNCaP, FOXA2-RES, rep1 LNCaP, FOXA2-RES,
- GSM8588824 LNCaP, FOXA2-RES, rep2 LNCaP, FOXA2-RES,
- GSM8588825 LNCaP, FOXA2-RES, rep3 LNCaP, FOXA2-RES,
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE265762 Individual RNA-seq for different prostate cancer cells and Lucap145.2 PDX treated by JQ1, AZD5153,ENZ or by FOXA1 and BRD4 gene knockdown 20 samples shares foxa1, prostate, rna-seq
- GSE281471 Targeting CD206+ macrophages disrupts the establishment of a key anti-tumor immune axis [Bulk RNA-seq] 243 samples shares targeting, disrupts, rna-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.